Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Novo Nordisk A/S

ClinicalTrials.gov Identifier:

NCT00383877

First received: October 3, 2006

Last updated: November 20, 2014

Last verified: November 2014

History of Changes

Purpose

This trial is conducted in China. This trial aims for a comparison of the effect on glycemic control in subjects with type 2 diabetes of insulin detemir or NPH-insulin given once daily at bedtime as add-on to oral anti-diabetic drug(s).

Condition	Intervention	Phase
Diabetes Diabetes Mellitus, Type 2	Drug: insulin detemir Drug: insulin NPH	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes

Resource links provided by NLM:

MedlinePlus related topics: Blood Sugar

Drug Information available for: Insulin Insulin human Insulin detemir

U.S. FDA Resources

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:

HbA1c [ Time Frame: after 20 weeks of treatment ]

Secondary Outcome Measures:

FBG [ Time Frame: after 20 weeks of treatment ]
Safety profile [ Time Frame: during 20 weeks treatment ]
Proportion of subjects achieving HbA1c less than or equal to 7.0% [ Time Frame: after 20 weeks of treatment ]
Within-subject variation of self measured blood glucose (SMBG) before breakfast during the trial at the end of the trial [ Time Frame: before breakfast during the trial at the end of the trial ]


Enrollment:	263
Study Start Date:	September 2006
Study Completion Date:	August 2007
Primary Completion Date:	August 2007 (Final data collection date for primary outcome measure)

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Type 2 diabetes
HbA1C greater than 7.5% and less than or equal to 11.0%
Currently on any oral antidiabetic drug (OAD) more than or equal to 3 months

Exclusion Criteria:

Previous acute treatment with insulin for more than 7 days.
Treatment with OAD(s) which does not adhere to the approval labeling.
Proliferate retinopathy or maculopathy that has required acute treatment within the last year.
Known hypoglycaemia unawareness or recurrent major hypoglycaemia, that may interfere with study participation as judged by the Investigator.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00383877

Locations


China

Beijing, China

Sponsors and Collaborators

Novo Nordisk A/S

Investigators


Study Director:	Global Clinical Registry (GCR, 1452)	Novo Nordisk A/S

More Information

Additional Information:

Clinical Trials at Novo Nordisk This link exits the ClinicalTrials.gov site


Responsible Party:	Novo Nordisk A/S
ClinicalTrials.gov Identifier:	NCT00383877 History of Changes
Other Study ID Numbers:	NN304-1684
Study First Received:	October 3, 2006
Last Updated:	November 20, 2014

Additional relevant MeSH terms:


Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Insulin, Globin Zinc Isophane insulin, beef	Insulin Insulin Detemir Isophane Insulin, Human Insulin, Isophane Hypoglycemic Agents Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 23, 2017

To Top